作者
Astrid K Gnekow, David A Walker, Daniela Kandels, Susan Picton, Giorgio Perilongo, Jacques Grill, Tore Stokland, Per Eric Sandstrom, Monika Warmuth-Metz, Torsten Pietsch, Felice Giangaspero, René Schmidt, Andreas Faldum, Denise Kilmartin, Angela De Paoli, Gian Luca De Salvo, Irene Slavc, Sue Picton, David Walker, Per Erik Sandstrom, Niels Clausen, Mikko Arola, Olafur Gisli Jonsson, Ofelia Cruz, Aurora Navajas, Anna Teijeiro, Chantal Kalifa, Marie-Anne Raquin, Joris Verlooy, Volkmar Hans, Wolfram Scheurlen, Johannes Hainfellner, James Ironside, Keith Robson, Kari Skullerud, David Scheie, Marie-Madeleine Ruchoux, Anne Jouvet, Dominique Figarella-Branger, Arielle Lellouch-Toubiana, Daniela Prayer, Milena Calderone, Tim Jaspan, Soren Jacob Bakke, Eli Vazquez, Dominique Couanet, Rolf D Kortmann, Karin Diekmann, Giovanni Scarzello, Roger Taylor, Knut Lote, Jordi Giralt, Christian Carrie, Jean Louis Habrand, Niels Soerensen, Thomas Czech, Paul Chumas, Bengt Gustavson, Michel Zerah, Bettina Wabbels, Maria Luisa Pinello, Alistair Fielder, Ian Simmons, Terje Christoffersen, Gabriele Calaminus, Knut Brockmann, Ronald Straeter, Friedrich Ebinger, Pablo Hernaiz-Driever, Herwig Lackner, Colin Kennedy, Adam Glaser, Bo Stromberg, Jose Ma Indiano, Chantal Rodary, Eric Bouffet, Didier Frappaz, Angela Emser, Suzanne Stephens, David Machin, Marie-Cécile Le Deley, Thore Egeland, Carolyn Freemann, Martin Schrappe, Richard Sposto
发表日期
2017/8/1
期刊
European journal of cancer
卷号
81
页码范围
206-225
出版商
Pergamon
简介
Background
The use of chemotherapy to manage newly diagnosed low grade glioma (LGG) was first introduced in the 1980s. One randomised trial has studied two- versus four-drug regimens with a duration of 12 months of treatment after resection.
Methods
Within the European comprehensive treatment strategy for childhood LGG, the International Society of Paediatric Oncology–Low Grade Glioma (SIOP LGG) Committee launched a randomised trial involving 118 institutions and 11 countries to investigate the addition of etoposide (100 mg/m2, days 1, 2 & 3) to a four-course induction of vincristine (1.5 mg/m2 × 10 wkly) and carboplatin (550 mg/m2 q 3 weekly) as part of 18-month continuing treatment programme. Patients were recruited after imaging diagnosis, resection or biopsy with progressive disease/symptoms. Some 497 newly diagnosed patients (M/F 231/266; median age 4.26 years (interquartile range (IQR …
学术搜索中的文章
AK Gnekow, DA Walker, D Kandels, S Picton… - European journal of cancer, 2017